{"id":487,"date":"2023-09-18T09:20:43","date_gmt":"2023-09-18T07:20:43","guid":{"rendered":"https:\/\/cfnorge.bwod.dev\/?page_id=487"},"modified":"2025-06-25T12:35:39","modified_gmt":"2025-06-25T10:35:39","slug":"fakta-om-cf","status":"publish","type":"page","link":"http:\/\/cfnorge.no.dev.exigo.no\/en\/cystisk-fibrose\/fakta-om-cf\/","title":{"rendered":"For pressen – Fakta om cystisk fibrose"},"content":{"rendered":"

[et_pb_section fb_built=»1″ next_background_color=»#ffffff» _builder_version=»4.21.0″ _module_preset=»default» background_color=»gcid-9e2f3af2-1007-4221-b250-8e35d98c5991″ background_enable_image=»off» background_size=»custom» background_image_width=»101%» custom_padding=»||90px|||» bottom_divider_style=»wave» locked=»off» global_colors_info=»{%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22background_color%22%93}»][et_pb_row _builder_version=»4.21.0″ _module_preset=»default» custom_padding=»11px||4px|||» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.21.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.21.0″ _module_preset=»default» header_font=»Poppins|600|||||||» header_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ custom_margin=»0px||0px||false|false» custom_padding=»0px||0px||false|false» global_colors_info=»{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22header_text_color%22%93}»]<\/p>\n

Facts about cystic fibrosis\u00a0<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»3_5,2_5″ _builder_version=»4.21.0″ _module_preset=»default» custom_margin=»0px||||false|false» custom_padding=»0px||||false|false» global_colors_info=»{}»][et_pb_column type=»3_5″ _builder_version=»4.21.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.21.0″ _module_preset=»default» text_font=»Poppins|300|||||||» text_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ text_font_size=»16px» text_line_height=»1.8em» global_colors_info=»{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22text_text_color%22%93}»]<\/p>\n

On this page, we have collected key information about cystic fibrosis in Norway. For medical and healthcare questions beyond what is written on this page, we recommend contacting the Norwegian Center for Cystic Fibrosis.\u00a0<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=»2_5″ _builder_version=»4.21.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_image src=»https:\/\/cfnorge.bwod.dev\/wp-content\/uploads\/2023\/08\/CF-Norge-Illustrasjonsbilde-lunger-1.png» title_text=»CF-Norge-Illustrasjonsbilde-lunger» _builder_version=»4.21.0″ _module_preset=»default» max_width=»70%» global_colors_info=»{}»][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ _builder_version=»4.21.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_row _builder_version=»4.21.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.21.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_image src=»https:\/\/cfnorge.bwod.dev\/wp-content\/uploads\/2024\/06\/nr2222.png» title_text=»nr2222″ align=»center» _builder_version=»4.21.0″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ custom_padding_last_edited=»on|phone» _builder_version=»4.21.0″ _module_preset=»default» custom_margin_tablet=»» custom_margin_phone=»0px||||false|false» custom_margin_last_edited=»on|phone» custom_padding_tablet=»» custom_padding_phone=»0px||||false|false» global_colors_info=»{}»][et_pb_row _builder_version=»4.21.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.21.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.21.0″ _module_preset=»default» header_font=»Poppins|600|||||||» header_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ header_line_height=»1.4em» custom_margin=»0px||12px||false|false» custom_padding=»0px||0px||false|false» global_colors_info=»{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22header_text_color%22%93}»]<\/p>\n

Causes, Diagnosis, Inheritance, and Prevalence of Cystic Fibrosis<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=»4.21.0″ _module_preset=»default» text_font=»Poppins|300|||||||» text_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ text_font_size=»16px» text_line_height=»1.8em» header_4_font=»|600|||||||» header_4_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ global_colors_info=»{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22text_text_color%22,%22header_4_text_color%22%93}»]<\/p>\n

<\/h4>\n

Cause<\/h4>\n

Cystic fibrosis is caused by a defect in a protein called the CFTR protein, resulting from a genetic mutation. There are over 2,000 known variants of this mutation. The defect in the CFTR protein leads to the production of excessively thick mucus. Since March 2012, all newborns in Norway have been screened for cystic fibrosis through the newborn screening program.<\/p>\n

[\/et_pb_text][et_pb_text _builder_version=»4.21.0″ _module_preset=»default» text_font=»Poppins|300|||||||» text_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ text_font_size=»16px» text_line_height=»1.8em» header_4_font=»|600|||||||» header_4_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ global_colors_info=»{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22text_text_color%22,%22header_4_text_color%22%93}»]<\/p>\n

Diagnosis<\/span><\/h4>\n

In Norway, all newborns are screened for cystic fibrosis via a program for newborn screening that started in March 2012. This makes it possible to diagnose the disease early and start treatment before the symptoms become severe. The diagnosis is usually confirmed by a sweat test that measures the amount of chloride in the sweat, as well as genetic tests to identify CFTR mutations.<\/p>\n

[\/et_pb_text][et_pb_text _builder_version=»4.21.0″ _module_preset=»default» text_font=»Poppins|300|||||||» text_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ text_font_size=»16px» text_line_height=»1.8em» header_4_font=»|600|||||||» header_4_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ global_colors_info=»{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22text_text_color%22,%22header_4_text_color%22%93}»]<\/p>\n

Arv<\/span><\/h4>\n

Cystisk fibrose arves autosomalt recessivt. Dette betyr at begge foreldrene m\u00e5 v\u00e6re b\u00e6rere av en mutasjon i CFTR-genet for at barnet skal kunne f\u00e5 sykdommen. Hvert barn har da 25% sjanse for \u00e5 arve to muterte gener (ett fra hver forelder) og utvikle cystisk fibrose, 50% sjanse for \u00e5 bli en frisk b\u00e6rer (arve ett mutert gen), og 25% sjanse for \u00e5 ikke arve noen muterte gener.<\/p>\n

About 150,000 Norwegians are carriers of the gene responsible for cystic fibrosis, although most are unaware until they have a child with the condition.<\/p>\n

<\/h4>\n

[\/et_pb_text][et_pb_text _builder_version=»4.21.0″ _module_preset=»default» text_font=»Poppins|300|||||||» text_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ text_font_size=»16px» text_line_height=»1.8em» header_4_font=»|600|||||||» header_4_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ global_colors_info=»{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22text_text_color%22,%22header_4_text_color%22%93}»]<\/p>\n

Forekomst<\/span><\/h4>\n

On average, 8-10 children are born with cystic fibrosis each year in Norway.<\/p>\n

<\/h4>\n

[\/et_pb_text][et_pb_text _builder_version=»4.21.0″ _module_preset=»default» text_font=»Poppins|300|||||||» text_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ text_font_size=»16px» text_line_height=»1.8em» header_4_font=»|600|||||||» header_4_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ global_colors_info=»{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22text_text_color%22,%22header_4_text_color%22%93}»]<\/p>\n

Treatment<\/span><\/h4>\n

Treatment for cystic fibrosis focuses on relieving symptoms and reducing complications. This includes physical therapy to loosen and remove tough mucus from the lungs, medications to reduce mucus production and treat infections, and nutritional therapy to ensure adequate nutrient absorption.<\/p>\n

In June 2022, the causative medication Kaftrio was approved for public funding. This applies to those with at least one copy of the most common CFTR mutation (F508del), which accounts for 85% of Norwegians with CF.<\/p>\n

For more information about diagnosis, symptoms, treatment, and newborn screening, visit the Norwegian Center for Cystic Fibrosis.<\/p>\n

[\/et_pb_text][et_pb_toggle title=»Transplantasjon som livreddende behandling ved cystisk fibrose» open_toggle_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ open_toggle_background_color=»RGBA(255,255,255,0)» closed_toggle_background_color=»gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05″ icon_color=»gcid-def3f79a-900d-4425-86b8-efdc1c9633a6″ toggle_icon=»P||divi||400″ use_icon_font_size=»on» icon_font_size=»20px» open_icon_color=»gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05″ open_toggle_icon=»O||divi||400″ open_use_icon_font_size=»on» open_icon_font_size=»20px» _builder_version=»4.21.0″ _module_preset=»default» title_text_color=»#FFFFFF» title_font=»|600|||||||» title_font_size=»18px» title_line_height=»1.4em» body_text_color=»gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24″ body_link_text_color=»gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05″ custom_margin=»10px||10px||false|false» custom_padding=»||||false|false» border_width_all=»0px» locked=»off» global_colors_info=»{%22gcid-def3f79a-900d-4425-86b8-efdc1c9633a6%22:%91%22icon_color%22%93,%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22open_toggle_text_color%22,%22body_text_color%22%93,%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22open_icon_color%22,%22closed_toggle_background_color%22,%22body_link_text_color%22%93}»]<\/p>\n

In some, the damage to the lungs will be so great that the disease becomes life-threatening. A lung transplant is then necessary.<\/p>\n